Gilead Sciences Announces Board and Executive Compensation Changes
Ticker: GILD · Form: 8-K · Filed: Jul 17, 2024 · CIK: 882095
| Field | Detail |
|---|---|
| Company | Gilead Sciences, INC. (GILD) |
| Form Type | 8-K |
| Filed Date | Jul 17, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: governance, executive-compensation, board-changes
Related Tickers: GILD
TL;DR
Gilead's board is shuffling, with exec pay plans updated. Keep an eye on who's in and out.
AI Summary
Gilead Sciences, Inc. announced on July 17, 2024, changes in its board of directors and executive compensation. The filing details the departure of certain directors and the election of new ones, alongside updates to compensatory arrangements for key officers.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, and future performance expectations.
Risk Assessment
Risk Level: low — This filing primarily concerns corporate governance and executive compensation, which typically have a low direct impact on immediate financial risk.
Key Players & Entities
- GILEAD SCIENCES, INC. (company) — Registrant
- July 17, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 333 Lakeside Drive, Foster City, California 94404 (address) — Principal executive offices
FAQ
What specific items are being reported under Item 5.02 of the 8-K?
Item 5.02 of this 8-K filing reports the departure of directors or certain officers, the election of directors, and the appointment of certain officers, as well as compensatory arrangements of certain officers.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on July 17, 2024.
What is the Commission File Number for Gilead Sciences, Inc.?
The Commission File Number for Gilead Sciences, Inc. is 0-19731.
What is the IRS Employer Identification Number for Gilead Sciences, Inc.?
The IRS Employer Identification Number for Gilead Sciences, Inc. is 94-3047598.
Where are Gilead Sciences, Inc.'s principal executive offices located?
Gilead Sciences, Inc.'s principal executive offices are located at 333 Lakeside Drive, Foster City, California 94404.
Filing Stats: 486 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-07-17 09:01:01
Key Financial Figures
- $0.001 — ch registered Common Stock, par value, $0.001 per share GILD The Nasdaq Global Se
Filing Documents
- tm2419649d1_8k.htm (8-K) — 25KB
- tm2419649d1_ex99-1.htm (EX-99.1) — 7KB
- tm2419649d1_ex99-1img001.jpg (GRAPHIC) — 4KB
- 0001104659-24-080355.txt ( ) — 208KB
- gild-20240717.xsd (EX-101.SCH) — 3KB
- gild-20240717_lab.xml (EX-101.LAB) — 33KB
- gild-20240717_pre.xml (EX-101.PRE) — 22KB
- tm2419649d1_8k_htm.xml (XML) — 3KB
02 Departure
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 17, 2024, Gilead Sciences, Inc., a Delaware corporation (the "Company"), announced that its Chief Medical Officer, Merdad V. Parsey, M.D., Ph.D., will leave the Company. No formal date has been established for Dr. Parsey's transition. Dr. Parsey will continue in his role while the Company works to identify a successor and thereafter to assist with the transition of his duties, which is expected to occur through the first quarter of 2025 or such other date as mutually agreed.
01 Financial Statements
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit Number Description 99.1 Press Release by Gilead Sciences, Inc. dated July 17, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GILEAD SCIENCES, INC. (Registrant) /s/ DEBORAH H. TELMAN Deborah H. Telman EVP, Corporate Affairs, General Counsel and Corporate Secretary Date: July 17, 2024